Literature DB >> 31749912

Synthesis and μ-Opioid Activity of the Primary Metabolites of Carfentanil.

Fu-Lian Hsu1, Andrew J Walz1, James M Myslinski1, Li Kong1, Michael G Feasel1, Tyler D P Goralski1, Tim Rose2, Nicholas J Cooper2, Neil Roughley2, Christopher M Timperley2.   

Abstract

Carfentanil is a synthetic opioid significantly more potent than clinically prescribed fentanyl. The primary metabolites of carfentanil, generated from human liver microsomes, were structurally confirmed through chemical synthesis. The synthesized compounds were evaluated for μ-opioid receptor (MOR) functional activity. Of the six metabolites assayed, a major metabolite showed comparable activity to the parent opioid. Three other metabolites showed significant MOR functional activity. The availability of the metabolites could aid improvements in the analysis of biomedical samples obtained from suspected human exposures to carfentanil and development of treatment protocols.
Copyright © 2019 American Chemical Society.

Entities:  

Year:  2019        PMID: 31749912      PMCID: PMC6862335          DOI: 10.1021/acsmedchemlett.9b00404

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  14 in total

Review 1.  Naloxone in opioid poisoning: walking the tightrope.

Authors:  S F J Clarke; P I Dargan; A L Jones
Journal:  Emerg Med J       Date:  2005-09       Impact factor: 2.740

Review 2.  The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs.

Authors:  M Hendset; T Haslemo; I Rudberg; H Refsum; E Molden
Journal:  Pharmacopsychiatry       Date:  2006-07       Impact factor: 5.788

3.  Efficacy and safety of naltrexone hydrochloride for antagonizing carfentanil citrate immobilization in captive Rocky Mountain elk (Cervus elaphus nelsoni).

Authors:  M W Miller; M A Wild; W R Lance
Journal:  J Wildl Dis       Date:  1996-04       Impact factor: 1.535

4.  Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry.

Authors:  Michael G Feasel; Ariane Wohlfarth; John M Nilles; Shaokun Pang; Robert L Kristovich; Marilyn A Huestis
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

5.  [11C]Carfentanil Binds Preferentially to μ-Opioid Receptor Subtype 1 Compared to Subtype 2.

Authors:  Olof Eriksson; Gunnar Antoni
Journal:  Mol Imaging       Date:  2015       Impact factor: 4.488

6.  The role of naloxone infusions in the treatment of overdoses of long half-life narcotic agonists: application to nor-methadone.

Authors:  G K Gourlay; K Coulthard
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

7.  Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies.

Authors:  Stefania Butini; Sandra Gemma; Margherita Brindisi; Giuseppe Borrelli; Andrea Lossani; Anna Maria Ponte; Andrea Torti; Giovanni Maga; Luciana Marinelli; Valeria La Pietra; Isabella Fiorini; Stefania Lamponi; Giuseppe Campiani; Daniela M Zisterer; Seema-Maria Nathwani; Stefania Sartini; Concettina La Motta; Federico Da Settimo; Ettore Novellino; Federico Focher
Journal:  J Med Chem       Date:  2011-02-14       Impact factor: 7.446

8.  Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx).

Authors:  Alexander Cole; Adrian Mutlow; Ramiro Isaza; James W Carpenter; David E Koch; Robert P Hunter; Betsy L Dresser
Journal:  J Zoo Wildl Med       Date:  2006-09       Impact factor: 0.776

9.  Analysis of clothing and urine from Moscow theatre siege casualties reveals carfentanil and remifentanil use.

Authors:  James R Riches; Robert W Read; Robin M Black; Nicholas J Cooper; Christopher M Timperley
Journal:  J Anal Toxicol       Date:  2012-09-20       Impact factor: 3.367

Review 10.  Carfentanil: a narrative review of its pharmacology and public health concerns.

Authors:  Jessica L S Leen; David N Juurlink
Journal:  Can J Anaesth       Date:  2019-01-21       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.